Abnormalities in micturition: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Undo revision 1479834 by Amandeep Singh (talk))
Line 11: Line 11:
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="3" rowspan="5" |Diseases
! colspan="3" rowspan="5" |Diseases
| colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
Line 24: Line 24:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Supra-pubic tenderness
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Supra-pubic tenderness
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin lesions
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin lesions
Line 38: Line 38:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hesitancy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hesitancy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nocturia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nocturia
!Dysuria
|-
|-
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammatory
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammatory
Line 43: Line 44:
| style="background: #DCDCDC; text-align: center;" |[[Lichen sclerosus]]
| style="background: #DCDCDC; text-align: center;" |[[Lichen sclerosus]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 65: Line 67:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 83: Line 86:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 102: Line 106:
| +
| +
| -
| -
|
| +
| +
|
|
Line 120: Line 125:
| +
| +
| -
| -
|
| +/-
| +/-
|
|
Line 138: Line 144:
| +
| +
| -
| -
|
| +/-
| +/-
|
|
Line 156: Line 163:
| +
| +
| -
| -
|
| -
| -
|
|
Line 174: Line 182:
| -
| -
| -
| -
|
| +
| +
|
|
Line 192: Line 201:
| +
| +
| +
| +
|
| +
| +
|
|
Line 209: Line 219:
| +
| +
| +
| +
|
|
|
|
|
Line 225: Line 236:
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Anatomic]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Anatomic]]
| style="background: #DCDCDC; text-align: center;" |[[Urethral stricture]]
| style="background: #DCDCDC; text-align: center;" |[[Urethral stricture]]
|
|
|
|
|
Line 245: Line 257:
|
|
|
|
| +
|
|
|
|
Line 262: Line 275:
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]]
| style="background: #DCDCDC; text-align: center;" |[[Spermicide|Spermicides]]
| style="background: #DCDCDC; text-align: center;" |[[Spermicide|Spermicides]]
|
|
|
|
|
Line 280: Line 294:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]]
| style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]]
|
|
|
|
|
Line 299: Line 314:
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]]
| style="background: #DCDCDC; text-align: center;" |[[Atrophic vaginitis]]
| style="background: #DCDCDC; text-align: center;" |[[Atrophic vaginitis]]
|
|
|
|
|
Line 317: Line 333:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Endometriosis]]
| style="background: #DCDCDC; text-align: center;" |[[Endometriosis]]
|
|
|
|
|
Line 336: Line 353:
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]]
| style="background: #DCDCDC; text-align: center;" |[[Bladder cancer]]
| style="background: #DCDCDC; text-align: center;" |[[Bladder cancer]]
|
|
|
|
|
Line 354: Line 372:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]]
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]]
|
|
|
|
|
Line 374: Line 393:
| style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]]
| style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]]
|
|
| +
|
|
|
|
Line 391: Line 411:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]]
| style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]]
|
|
|
|
|
Line 410: Line 431:
| style="background: #DCDCDC; text-align: center;" |[[Trauma]]
| style="background: #DCDCDC; text-align: center;" |[[Trauma]]
|
|
|±
|
|
|
|

Revision as of 20:45, 27 June 2018

Micturation Abnormalities Microchapters

Overview

Causes

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Classification

Causes

Abnormalities of Micturation Differential Diagnosis

Differentiating the diseases that can cause abnormality in micturation:

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging
Low back pain Fever Urinary symptoms Supra-pubic tenderness Skin lesions Other CBC Electrolytes Urinalysis Ultrasonography CT scan Other
Dribbling Hesitancy Nocturia Dysuria
Inflammatory Dermatological disorders Lichen sclerosus - - - + - - -
Behcet's syndrome - - - + - -
Contact dermatitis - - - + - -
Infectious diseases Cystitis - + +/- + - +
Urethritis - + - + - +/-
Pyelonephritis + + - + - +/-
Vulvovaginitis - + + + - -
Cervicitis +/- + +/- - - +
Prostatitis + +/- + + + +
Epididymoorchitis - +/- + +
Non-inflammatory Anatomic Urethral stricture
Benign prostatic hyperplasia (BPH) +
Drug Spermicides
Cyclophosphamide
Endocrine disorders Atrophic vaginitis
Endometriosis
Malignancy Bladder cancer
Vulvovaginal cancer
Iatrogenic Genitourinary instrumentation +
Pelvic irradiation
Trauma ±
Retrieved from "https://www.wikidoc.org/index.php?title=Abnormalities_in_micturition&oldid=1479836"